A retrospective analysis of more than 100 patients under 65 years of age with de novo AML indicated that higher percentages of CD34+/CD38−/CD123+ leukemia cells at diagnosis associate with enhanced probability of resistance to intensive chemotherapy and shorter disease-free survival [42]. This evidence concerns the gene CD38 and acute myeloid leukemia.